pre-update Archives

Publication

Synergistic Interactions between Sorafenib and Everolimus in Pancreatic Cancer Xenografts in Mice

Molecular targeting of cellular signaling pathways is a promising approach in cancer therapy, but often…

Danielle Pillsbury2013 年 5 月 1 日

Publication

Physiologically-based Pharmacokinetic Models for Everolimus and Sorafenib in Mice

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved as an immunosuppressant and for…

Danielle Pillsbury2013 年 5 月 1 日

Publication

Brain Extracellular γ-hydroxybutyrate Concentrations are Decreased by L-lactate in Rats: Role in the Treatment of Overdoses

L-lactate represents a potential treatment for GHB overdose by inhibiting GHB renal reabsorption mediated by…

Danielle Pillsbury2013 年 5 月 1 日

Publication

Do Children Have the Same Vulnerability to Metabolic Drug-drug Interactions as Adults? A Critical Analysis of the Literature

Many drug–drug interactions (DDIs) in the pediatric population are managed based on data generated in…

Danielle Pillsbury2013 年 5 月 1 日

Publication

A Physiologically-based Pharmacokinetic Modeling Approach to Predict Disease-drug Interactions: Suppression of CYP3A by IL-6

Elevated cytokine levels are known to downregulate expression and suppress activity of cytochrome P450 enzymes…

Danielle Pillsbury2013 年 4 月 10 日

Publication

A Physiologically-based Pharmacokinetic (PBPK) Approach to Evaluate Pharmacokinetics in Patients with Cancer

Potential differences in pharmacokinetics (PK) between healthy subjects and patients with cancer were investigated using…

Danielle Pillsbury2013 年 4 月 1 日

Publication

Effects of Monocarboxylate Transporter Inhibition on the Oral Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone

Respiratory depression and death secondary to respiratory arrest have occurred after oral overdoses of γ-hydroxybutyrate…

Danielle Pillsbury2013 年 4 月 1 日

刊物

Model-based Drug Development in Oncology: What’s Next?

Model-based estimates of tumor growth inhibition (TGI) metrics have the potential to enhance learning in…

Danielle Pillsbury2013 年 4 月 1 日

Publication

Model-supported Development of CS-8635: A Fixed-dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide

CS-8635, a fixed-dose triple combination of olmesartan, amlodipine, and hydrochlorothiazide, was developed to address the…

Danielle Pillsbury2013 年 4 月 1 日

Publication

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2,…

Danielle Pillsbury2013 年 3 月 28 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

pre-update

Synergistic Interactions between Sorafenib and Everolimus in Pancreatic Cancer Xenografts in Mice

Physiologically-based Pharmacokinetic Models for Everolimus and Sorafenib in Mice

Brain Extracellular γ-hydroxybutyrate Concentrations are Decreased by L-lactate in Rats: Role in the Treatment of Overdoses

Do Children Have the Same Vulnerability to Metabolic Drug-drug Interactions as Adults? A Critical Analysis of the Literature

A Physiologically-based Pharmacokinetic Modeling Approach to Predict Disease-drug Interactions: Suppression of CYP3A by IL-6

A Physiologically-based Pharmacokinetic (PBPK) Approach to Evaluate Pharmacokinetics in Patients with Cancer

Effects of Monocarboxylate Transporter Inhibition on the Oral Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone

Model-based Drug Development in Oncology: What’s Next?

Model-supported Development of CS-8635: A Fixed-dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

订阅时事通讯

快捷链接

解决方案

联系我们